PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-11-25
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT01248494
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Massachusetts General Hospital, Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Phase 2
Withdrawn
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240941
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Phase 1
Withdrawn
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Registration Number
- NCT01240928
Opioid Titration in the Hospice Setting: Barriers Assessment and Modification of the Model Order Sheet and Protocol
Completed
- Conditions
- Cancer Pain
- Interventions
- Other: interview, focus group and structured surveyOther: Individual patient interview, focus group and structured survey
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT01230515
- Locations
- 🇺🇸
Vanderbilt-Ingam Cancer Center, Nashville, Tennessee, United States
PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer
Phase 2
Terminated
- Conditions
- Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT01227018
- Locations
- 🇺🇸
The Jones Clinic, Memphis, Tennessee, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
PET/CT Evaluation of Treatment Response in Breast Cancer
Not Applicable
Terminated
- Conditions
- Breast Cancer
- Interventions
- Radiation: Radiopharmaceutical Administration [18F]-FDG
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01222416
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients
Phase 1
Completed
- Conditions
- Adult Stem Cell Hematopoetic Transplant
- Interventions
- Biological: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)Biological: Standard Dose Trivalent Inactivated Flu Vaccine
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT01215734
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Clinical Trials Information Program, Nashville, Tennessee, United States
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- Drug: DVT prophylaxisDrug: Bisphosphonates
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT01215344
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Tennessee Cancer Institute, Boston Baskin Cancer Group, Memphis, Tennessee, United States
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
Phase 1
Completed
- Conditions
- Rectal Cancer
- Interventions
- Device: PET imaging with [18F]-FLTDrug: [18F]-fluorodeoxythymidine
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT01207895
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
Recruiting
- Conditions
- Melanoma
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 3000
- Registration Number
- NCT01205815
- Locations
- 🇺🇸
Vanderbitl-Ingram Cancer Center, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath